Insmed Incorporated (FRA:IM8N)

Germany flag Germany · Delayed Price · Currency is EUR
179.00
+2.00 (1.13%)
At close: Dec 4, 2025
148.61%
Market Cap 37.40B
Revenue (ttm) 381.00M
Net Income (ttm) -1.01B
Shares Out n/a
EPS (ttm) -5.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85
Average Volume 62
Open 176.00
Previous Close 177.00
Day's Range 176.00 - 179.00
52-Week Range 58.00 - 185.00
Beta n/a
RSI 54.91
Earnings Date Feb 27, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1988
Employees 1,271
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol IM8N
Full Company Profile

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.